CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Down 64.8% in December

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the recipient of a large decline in short interest in December. As of December 31st, there was short interest totalling 471,100 shares, a decline of 64.8% from the December 15th total of 1,340,000 shares. Based on an average trading volume of 22,860,000 shares, the short-interest ratio is currently 0.0 days.

CNS Pharmaceuticals Price Performance

Shares of NASDAQ CNSP traded down $0.00 during midday trading on Monday, reaching $0.12. 26,333,594 shares of the company traded hands, compared to its average volume of 69,315,969. The company has a market cap of $6.73 million, a price-to-earnings ratio of 0.00 and a beta of 2.52. The stock has a 50-day moving average price of $0.11 and a 200 day moving average price of $0.30. CNS Pharmaceuticals has a 52 week low of $0.10 and a 52 week high of $46.75.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.